Outlook Therapeutics (OTLK) Change in Accured Expenses (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Change in Accured Expenses of $4.4 million for Q1 2026, up 541.08% year-over-year from $684384.2 in Q1 2025, and up 1582.48% quarter-over-quarter from -$295952.0 in Q4 2025.
Outlook Therapeutics (OTLK) Change in Accured Expenses (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Change in Accured Expenses for 12 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 541.08% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $6.6 million (up 1059.8% YoY), while the FY2025 annual figure was $1.7 million, up 247.79% from the prior year.
- Change in Accured Expenses advanced to $4.4 million in Q1 2026 per OTLK's latest filing, from -$295952.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $5.0 million in Q4 2022 and bottomed at -$5.6 million in Q3 2023.
- Historically, Change in Accured Expenses has averaged $276468.7 across 5 years, with a median of -$152635.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 3543.58% — and 2025, when it soared 638.75%.
- Outlook Therapeutics' Change in Accured Expenses stood at $5.0 million in 2022, then tumbled by 73.21% to $1.3 million in 2023, then tumbled by 88.53% to $153764.0 in 2024, then sank by 292.47% to -$295952.0 in 2025, then soared by 1582.48% to $4.4 million in 2026.
- Business Quant data shows OTLK's Change in Accured Expenses at $4.4 million in Q1 2026, -$295952.0 in Q4 2025, and $354702.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | -5.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.39 Mn |
| Mar 31, 2026 | 4.39 Mn |
| Dec 31, 2025 | -295,952.00 |
| Dec 31, 2025 | -295,952.00 |
| Sep 30, 2025 | 354,702.00 |
| Sep 30, 2025 | 354,702.00 |
| Jun 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | -994,707.00 |
| Mar 31, 2025 | -994,707.00 |
| Dec 31, 2024 | 153,764.00 |
| Dec 31, 2024 | 153,764.00 |
| Sep 30, 2024 | 556,554.00 |
| Sep 30, 2024 | 556,554.00 |
| Jun 30, 2024 | -407,694.00 |
| Jun 30, 2024 | -407,694.00 |
| Mar 31, 2024 | -998,162.00 |
| Mar 31, 2024 | -998,162.00 |
| Dec 31, 2023 | 1.34 Mn |
| Dec 31, 2023 | 1.34 Mn |